We thought the answer was YES.
There was a set of univariate sensitivity analyses in which many variables were changed (page 2458). However, the point estimates of effectiveness for CHD of intensive hypertensive therapy from the clinical trial was not used because it did not reach statistical significance.
Using the UKPDS figures (which are particularly relevant in the UK) in the scenario for the control of glucose levels, intensive treatment became cost saving with a cost per QALY of approximately $‑6,000/QALY (page 2549 figure 3A) (NB the minus). This which would make this the most cost effective option of the three in the UK.